61 related articles for article (PubMed ID: 35324532)
1. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract][Full Text] [Related]
2. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
3. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
McCoach CE; Rolfo C; Drilon A; Lacouture M; Besse B; Goto K; Zhu VW; Tan DSW; Farajian S; Potter LA; Kherani JF; Soldatenkova V; Olek EA; Muehlenbein CE; Park K
J Thorac Oncol; 2022 Jun; 17(6):768-778. PubMed ID: 35183775
[TBL] [Abstract][Full Text] [Related]
7. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
[TBL] [Abstract][Full Text] [Related]
8. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract][Full Text] [Related]
10. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
[TBL] [Abstract][Full Text] [Related]
11. Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and
Dong SS; Dong W; Tan YF; Xiao Q; Wang TL
Front Oncol; 2024; 14():1370901. PubMed ID: 38690167
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial.
Raez LE; Kang H; Ohe Y; Khanal M; Han Y; Szymczak S; Barker SS; Gilligan AM
ESMO Open; 2024 May; 9(5):103444. PubMed ID: 38749381
[TBL] [Abstract][Full Text] [Related]
13. Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma.
McKinley BJ; Coston TW; Starr JS
Oncologist; 2024 Mar; ():. PubMed ID: 38478398
[TBL] [Abstract][Full Text] [Related]
14. Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.
Deschler-Baier B; Konda B; Massarelli E; Hu MI; Wirth LJ; Xu X; Wright J; Clifton-Bligh RJ
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38661071
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report.
Torrado C; Feng J; Faour E; Leighl NB
JTO Clin Res Rep; 2024 Apr; 5(4):100647. PubMed ID: 38550296
[TBL] [Abstract][Full Text] [Related]
16. Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.
Hashimoto K; Kaira K; Imai H; Shiono A; Kagamu H
J Chemother; 2024 May; ():1-3. PubMed ID: 38766697
[TBL] [Abstract][Full Text] [Related]
17. Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition.
Barsouk A; Elghawy O; Stone S; Singh A
Anticancer Drugs; 2024 Apr; ():. PubMed ID: 38696710
[TBL] [Abstract][Full Text] [Related]
18. Selpercatinib and Pseudo-Decreases in Kidney Function.
Izzedine H; Bouderlique E; Besse B
N Engl J Med; 2024 Apr; 390(13):1241-1243. PubMed ID: 38598583
[No Abstract] [Full Text] [Related]
19. Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma.
Weiler D; Pérez Lago MDS
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38763961
[No Abstract] [Full Text] [Related]
20. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Offin M; Guo R; Wu SL; Sabari J; Land JD; Ni A; Montecalvo J; Halpenny DF; Buie LW; Pak T; Liu D; Riely GJ; Hellmann MD; Benayed R; Arcila M; Kris MG; Rudin CM; Li BT; Ladanyi M; Rekhtman N; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 31192313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
